Z17.2
Progesterone receptor status
Clinical Classification Guidelines
Medical Intelligence & Overview
Progesterone receptor status refers to the presence of specific proteins called progesterone receptors in breast cancer cells. Determining the receptor status helps healthcare providers to understand how the cancer might grow and respond to treatment. This test is an essential part of breast cancer diagnosis and management, guiding personalized treatment plans. Although coded under ICD-10 with Z17.2, which generally signifies bone marrow transplant status, in this context, it's used for indicating receptor status assessment.
Causes & Symptoms
Clinical Causes: Development of breast cancer characterized by hormone receptor expression Genetic factors influencing receptor presence Hormonal changes affecting breast tissue Environmental factors potentially impacting receptor expression
Key Symptoms: Usually, no direct symptoms relate to receptor status itself, as it is part of microscopic tissue analysis. Symptoms of breast cancer may include a lump in the breast, changes in breast shape or size, nipple discharge, or skin changes, which prompt testing that includes receptor status evaluation.
Diagnostic & Treatment
Diagnosis Path: Determining progesterone receptor status involves tissue testing following a biopsy or surgical removal of breast tumor tissue. The process includes:
Treatment Protocols: While the diagnosis and assessment of progesterone receptor status guide treatment decisions, the treatment plan typically includes:
Clinical Advice & FAQs
Billing Guidance
Is Z17.2 a billable ICD-10 code?
Yes, Z17.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z17.2?
Clinical documentation must specify the nature of Progesterone receptor status and any associated comorbidities for accurate reporting.
Cite this Clinical Reference